Abstract
Background Loss of functional capacity is one of the hallmarks in cardiovascular aging. Cocoa flavanols (CF) exert favorable effects on endothelial function, blood pressure, and inflammation. These cardiovascular health markers worsen with increasing age and limit functional exercise capacity.
Aim To investigate the effect of CF on cardiorespiratory-fitness in healthy elderly.
Methods In a randomized, double-masked, placebo-controlled, parallel-group dietary intervention trial, 68 healthy elderly (55-79 years, 28 female) received either 500 mg of CF or a nutrient-matched control capsule twice a day for 30 days. Primary endpoint was defined as peak oxygen consumption (VO2) in a cardiopulmonary exercise test (CPET). Secondary endpoints were oxygen pulse (VO2/heart rate (HR)), resting blood pressure (BP), and resting vascular function.
Results After 30 days of CF intake peakVO2 increased by 190 ml/min (95% CI 1-371 ml/min) and peakVO2/kg by 2.5 ml/(min*kg) (95% CI 0.30-4.2 ml/(min*kg)). O2-pulse increased by 1.7 ml (95% CI 0.29-3.2 ml) and max exercise capacity by 9.6 W (95% CI 2.1-17.7 W). CF decreased resting systolic and diastolic BP by 5.4 mmHg (95% CI -10.7 - -0.1 mmHg) and 2.9 mmHg (95% CI (-) 5.5-(-) 0.4 mmHg), respectively. Flow-mediated vasodilation (FMD) increased by an absolute 1.3% (95% CI 0.76-1.79 %) in the CF group. Indexes of pulmonary function were not affected. No changes for primary and secondary endpoints were detected in control.
Conclusion CF substantially improve markers of cardiorespiratory fitness in healthy elderly humans highlighting their potential to preserve cardiovascular health with increasing age.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05782309
Clinical Protocols
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval the ethics committee of the Heinrich Heine University Duesseldorf (Approval Number R5761R).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Due to graphical problems, figures were not displayed in the original form. corrected
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations
- BMI
- body mass index
- BP
- Blood pressure
- BSA
- body surface area
- CAP
- central aortic pressure
- CF
- Cocoa flavanol
- CPET
- cardiopulmonary exercise testing
- CVD
- cardiovascular disease
- FMD
- flow-mediated vasodilation
- HR
- heart rate
- PeakVO2
- maximum oxygen consumption
- RA
- radial artery
- RER
- respiratory exchange ratio
- VO2
- volume flow of oxygen
- VT
- ventilatory threshold
